Judge Dismisses Eli Lilly Lawsuit Against Telehealth Company Over Weight Loss Drugs

By Editorial Team

A California federal court has dismissed a lawsuit filed by Eli Lilly against a telehealth company and related entities regarding the compounding of its weight loss drugs Mounjaro and Zepbound. The court ruled that Eli Lilly’s complaint did not plausibly allege claims under the Lanham Act and the state’s false advertising and consumer protection laws.

The lawsuit, which was brought by Eli Lilly, a pharmaceutical giant, alleged that the telehealth company and other entities were involved in the improper compounding of its popular weight loss drugs. However, the court found that the claims made by Eli Lilly were not supported by sufficient evidence to proceed with the case.

The California federal court’s decision highlights the importance of providing substantial evidence and meeting the legal standards required to pursue claims under the Lanham Act and state consumer protection laws.

For more information on this case and other legal news, subscribe to Law360 for access to in-depth analysis, expert insights, and real-time alerts on legal developments.